Sign Out
Neither crisaborole nor its 2 main metabolites are expected to cause drug interactions by induction or inhibition of cytochrome P450 (CYP) enzymes based on in vitro and in vivo data (see Pharmacology: Pharmacokinetics under Actions).
Based on in vitro data, concomitant administration of STAQUIS and CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir) or CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) can increase systemic crisaborole concentrations (see Pharmacology: Pharmacokinetics under Actions).
STAQUIS has not been evaluated in combination with other cutaneous medicinal products including emollients to treat mild to moderate atopic dermatitis.
